Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy

Lönnkvist, Maria; Theodorsson, Elvar; Holst, Mikael; Ljung, Tryggve; Hellström, Per M.

doi:10.3109/00365521.2010.539253

Cited by 34 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recently published study on 60 IBD patients (34 with CD and 26 with UC), normalization of calprotectin after infliximab or adalimumab induction therapy predicted sustained clinical remission during scheduled maintenance therapy in the majority of patients [30]. A similar decrease of calprotectin after infliximab therapy has been described in several other studies [11,14,31]. Calprotectin and lactoferrin were correlated with endoscopic activity during anti-TNF-α therapy and seemed to be a good marker of MH [11].…”

Section: Calprotectinsupporting

confidence: 49%

“…A series of new biomarkers including nitric oxide, the soluble form of urokinase-type plasminogen activator receptor, ghrelin or endothelin-1 have been examined for assessment of disease activity and response to anti-inflammatory treatment [14]. However, only preliminary data from pilot studies have so far been published.…”

Section: New Markersmentioning

confidence: 99%

“…Additionally, Yoon et al [13 ]showed that a higher Mayo score was strongly associated with poor outcome indicating steroid dependency and proctocolectomy. In another study in 22 CD patients, the Harvey-Bradshaw Index significantly decreased after a single infusion of infliximab [14]. …”

Section: Clinical Scoresmentioning

confidence: 99%

“…With its limit of detection of 0.2 mg/l, it may detect low-grade inflammation even in asymptomatic patients [14]. However, the correlation between high-sensitive CRP and histological activity in UC is low [24].…”

Section: C-reactive Proteinmentioning

confidence: 99%

See 3 more Smart Citations

Monitoring of Therapy for Inflammatory Bowel Disease

Burri

Beglinger

Lehmann³

2012

Digestion

View full text Add to dashboard Cite

The monitoring of inflammatory bowel disease (IBD) based on clinical symptoms and activity scores alone has major drawbacks. Despite clinical remission, in many patients with ongoing low-grade inflammation and activity scores, there is a tendency to underestimate IBD activity as parameters depend on the subjective symptoms of the patients. C-reactive protein might identify patients with low-grade inflammation, especially in Crohn’s disease, but sensitivity remains limited. Recently, fecal markers of inflammation have been shown to correlate well with endoscopic disease activity and to predict relapse. However, data on serial measurements to guide therapy are scarce. The role of anti-TNF-α antibodies and plasma TNF-α concentrations in IBD therapy is currently unclear and needs to be defined further. The goal of improving disease outcome has not been demonstrated for any noninvasive biomarker so far.

show abstract

Section: Calprotectinsupporting

confidence: 49%

Section: New Markersmentioning

confidence: 99%

Section: Clinical Scoresmentioning

confidence: 99%

Section: C-reactive Proteinmentioning

confidence: 99%

See 2 more Smart Citations

Monitoring of Therapy for Inflammatory Bowel Disease

Burri

Beglinger

Lehmann³

2012

Digestion

View full text Add to dashboard Cite

show abstract

“…Our finding that suPAR levels in healthy controls were similar to those reported in comparable children (15)(16)(17)(18) imparts validity to the suPAR levels we measured in our patients with forms of CKD. Numerous studies have shown serum suPAR levels to be increased with nonspecific inflammation or immune activation (15)(16)(17)(18)(19)(20)(21)(22)(23). In fact, urokinase plasminogen activator receptor is expressed on various cell types (neutrophils, lymphocytes, monocytes, and endothelial and tumor cells).…”

Section: Discussionmentioning

confidence: 99%

Serum Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Idiopathic FSGS in Children

Bock

Price

Gallon

et al. 2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives FSGS is the primary cause of childhood nephrotic syndrome leading to ESRD. Permeability factors, including circulating serum soluble urokinase-type plasminogen activator receptor (suPAR), have been postulated as putative causes in adults with primary FSGS. Similar results have yet to be proven in children.Design, setting, participants, & measurements This cross-sectional single-center study assessed the association of serum suPAR in children with FSGS or other glomerular and nonglomerular kidney diseases.Results This study examined 110 samples retrieved from 99 individuals (between January 2011 and April 2012), aged 1-21 years; of these individuals, 20 had primary FSGS, 24 had non-FSGS glomerular disease, 26 had nonglomerular kidney disease, and 29 were healthy controls. suPAR levels were not significantly different in children with FSGS, non-FSGS glomerular disease, and healthy controls (P.0.05). However, suPAR levels (median [25%-75%]) were higher in children with nonglomerular kidney disease (3385 pg/ml ) versus FSGS (2487 pg/ml [2191-3351]; P,0.05). Female patients with nephrotic-range proteinuria (U-Pr/Cr .2) had lower suPAR levels than those without proteinuria (2380 pg/ml versus 3125 pg/ml , respectively; P,0.001). This trend was not seen among male participants; suPAR levels in all female participants were lower than in male participants (P=0.03). Thirty-four patients studied were kidney transplant recipients; transplant status was not associated with suPAR levels in patients with FSGS or non-FSGS diagnoses, independent of proteinuria, race, or sex (P.0.05).Conclusions On the basis of these results, circulating suPAR is unlikely the leading cause for childhood idiopathic FSGS.

show abstract